Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors

The purpose of the study is to find some biomarkers to predict the the adverse events of Immune Checkpoint Inhibitors monotherapy or plus platinum based chemotherapy in lung cancer.

Trial Details

NCT ID

NCT05055908

Phase

PHASE3

Sponsor

Hunan Province Tumor Hospital

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

Pemetrexed plus Pembrolizumab
Pembrolizumab
Pemetrexed

Locations (sample)

Changsha, Hunan, China|28.19874,112.97087

Key Eligibility Criteria

Understand the requirements and contents of the clinical trial, and provide a signed and dated informed consent form.
Age ≥ 18 years.
Histologically or cytologically confirmed lung cancer.
Treated with Immune Checkpoint Inhibitors with or without chemotherapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →